<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article101</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/MARINER" style="display:block; margin-bottom:10px;">MARINER Original</a></li>
<h2><strong>MARINER</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Extended Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients". The New England Journal of Medicine. 2018.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does extended thromboprophylaxis with rivaroxaban in acutely ill medical patients after hospital discharge reduce the risk of symptomatic venous thromboembolism?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In acutely ill medical patients, extended thromboprophylaxis with rivaroxaban after hospital discharge did not significantly reduce the risk of symptomatic venous thromboembolism when compared with placebo.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the knowledge cutoff date, guidelines had not yet been established reflecting the results of this trial.<br/>
<br/>
<h2><strong>Design</strong></h2><br/><br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion Criteria: Patients aged ≥40 years hospitalized for ≥3 to ≤10 days with acute medical illnesses and additional risk factors for venous thromboembolism<br/>
- Exclusion Criteria: Patients with conditions requiring long-term anticoagulant or dual antiplatelet therapy, active cancer, recent significant bleeding, or other contraindications to rivaroxaban<br/>
- Baseline Characteristics: Similar across intervention and placebo groups<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Patients were randomized at hospital discharge to receive either rivaroxaban (10 mg daily or 7.5 mg daily for those with moderate renal impairment) or placebo for 45 days.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary Outcome: Composite of symptomatic venous thromboembolism or death related to venous thromboembolism<br/>
- Principal Safety Outcome: Major bleeding<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
The low incidence of venous thromboembolism–related events in the placebo group (1.10%) and the inclusion of sudden death of unknown cause may have affected the specificity of venous thromboembolism–related death as an outcome.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
This trial was funded by Janssen Research and Development.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Additional details and comprehensive data analysis are available in the full text of the article in The New England Journal of Medicine.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
